Similar articles

• Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer.

  Wolff AC, Davidson NE. Wolff AC, et al. J Clin Oncol. 2006 Nov 1;24(31):4949-51. doi: 10.1200/JCO.2006.07.9160. J Clin Oncol. 2006. PMID: 17075110 No abstract available.
• Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: an old(er) problem.

  Schott A, Hayes DF. Schott A, et al. J Clin Oncol. 2004 Dec 1;22(23):4660-2. doi: 10.1200/JCO.2004.07.961. Epub 2004 Oct 25. J Clin Oncol. 2004. PMID: 15505274 No abstract available.
• Dose density in breast cancer: a simple message?

  Lin NU, Gelman R, Winer EP. Lin NU, et al. J Natl Cancer Inst. 2005 Dec 7;97(23):1712-4. doi: 10.1093/jnci/dji438. J Natl Cancer Inst. 2005. PMID: 16333021 No abstract available.
• Adjuvant therapy for premenopausal patients with early breast cancer.

  Kurebayashi J. Kurebayashi J. Curr Opin Obstet Gynecol. 2008 Feb;20(1):51-4. doi: 10.1097/GCO.0b013e3282f226bd. Curr Opin Obstet Gynecol. 2008. PMID: 18197006 Review.
• Recent advances in the hormonal treatment of breast cancer.

  Boughey JC, Buzdar AU, Hunt KK. Boughey JC, et al. Curr Probl Surg. 2008 Jan;45(1):13-55. doi: 10.1067/j.cpsurg.2007.10.004. Curr Probl Surg. 2008. PMID: 18206436 Review. No abstract available.